Timothy S. Lancaster

Timothy S. Lancaster

Auto-generated profile, based on publicly available information

Timothy S. Lancaster

Division of Cardiothoracic Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St Louis, Mo

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2017 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
JGJason W. Greenberg
Jason W. Greenberg
TLTimothy S. Lancaster
Timothy S. Lancaster
RSRichard B. Schuessler
Richard B. Schuessler
SMSpencer J. Melby
Spencer J. Melby
Postoperative atrial fibrillation (POAF) is a common, expensive and potentially morbid complication following cardiac surgery. POAF occurs in around 35% of cardiac surgery cases and has a peak incidence on postoperative day 2. Patients who develop POAF incur on average $10 000–$20 000 in additional hospital treatment costs, 12–24 h of prolonged ICU time, and an additional 2 to 5 days in the hospital. POAF has been identified as an independent predictor of numerous adverse outcomes, including a 2- to 4-fold increased risk of stroke, reoperation for bleeding, infection, renal or respiratory failure, cardiac arrest, cerebral complications, need for permanent pacemaker placement, and a 2-fold increase in all-cause 30-day and 6-month mortality. The pathogenesis of POAF is incompletely understood but likely involves interplay between pre-existing physiological components and local and systemic inflammation. POAF is associated with numerous risk factors including advanced age, pre-existing conditions that cause cardiac remodelling and certain non-cardiovascular conditions. Clinical management of POAF includes both prophylactic and therapeutic measures, although the efficacy of many interventions remains in question. This review provides a comprehensive and up-to-date summary of the pathogenesis of POAF, outlines current clinical guidelines for POAF prophylaxis and management, and discusses new avenues for further investigation.

1 November 2015 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MHMatthew C. Henn
Matthew C. Henn
TLTimothy S. Lancaster
Timothy S. Lancaster
JMJacob R. Miller
Jacob R. Miller
LSLaurie A. Sinn
Laurie A. Sinn
RSRichard B. Schuessler
Richard B. Schuessler
RDRalph J. Damiano
Ralph J. Damiano

1 July 2016 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JMJacob R. Miller
Jacob R. Miller
KSKathleen E. Simpson
Kathleen E. Simpson
DEDeirdre J. Epstein
Deirdre J. Epstein
TLTimothy S. Lancaster
Timothy S. Lancaster
MHMatthew C. Henn
Matthew C. Henn
UBUmar S Boston
Umar S Boston

1 October 2016 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
TLTimothy S. Lancaster
Timothy S. Lancaster
MSMatthew R. Schill
Matthew R. Schill
JGJason W. Greenberg
Jason W. Greenberg
MMMarc R. Moon
Marc R. Moon
RSRichard B. Schuessler
Richard B. Schuessler
SMSpencer J. Melby
Spencer J. Melby

1 May 2017 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
TLTimothy S. Lancaster
Timothy S. Lancaster
JMJacob R. Miller
Jacob R. Miller
DEDeirdre J. Epstein
Deirdre J. Epstein
NDNicholas C. DuPont
Nicholas C. DuPont
SSStuart C. Sweet
Stuart C. Sweet
PEPirooz Eghtesady
Pirooz Eghtesady

1 February 2009 in Endocrinology
Verified
Journal Article
Closed access
JNJennifer L. Novotny
Jennifer L. Novotny
ASAmy M. Simpson
Amy M. Simpson
NTNanette J. Tomicek
Nanette J. Tomicek
TLTimothy S. Lancaster
Timothy S. Lancaster
DKDonna H. Korzick
Donna H. Korzick
The effects of estrogen deficiency on the loss of cardioprotection with advancing age are complex and poorly understood. A major focus of the current study was to uncover a cardioprotective role for rapid, nongenomic estrogen receptor (ER) signaling in the aged female myocardium. We hypothesized that selective ERalpha activation in aged females would reduce infarct size in part, through reversal of age-associated reductions in mitochondrial protein kinase Cepsilon (PKCepsilon). Hearts isolated from adult (6 month old) and aged (23-24 months old) female F344 rats with ovaries removed (n = 20 per group) were subjected to ischemia/reperfusion (47 min global ischemia). Rats were injected sc with the ERalpha agonist propylpyrazole triol (PPT) or vehicle 45 min before heart isolation (5 microg/kg). Infarct size was greatest in aged vs. adult ovariectomized rats, significantly reduced by PPT, and the protection reversed by prior administration of the ER inhibitor ICI 182,780 (3 mg/kg). Increased ERalpha particulate targeting occurred after PPT in conjunction with reversal of age-related reductions in nuclear PKCepsilon, mitochondrial PKCepsilon and pAkt (P < 0.05). PPT also increased mRNA levels for the PKCepsilon anchoring protein, receptor for activated C kinase2 (RACK2; P < 0.05). Our data suggest, for the first time, that selective ERalpha activation reduces ischemic injury in the aged, estrogen-deficient heart through a mechanism involving nongenomic redistribution of ERalpha and PKCepsilon activation. A novel feed-forward transcriptional mechanism to potentially enhance PKCepsilon-RACK2 interactions was also observed. Collectively, our findings may provide key insight into developing targeted therapeutic interventions in postmenopausal women to reduce ischemia/reperfusion injury, including selective ERalpha mimetics.